Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling

• Published in: Current Issues in Molecular Biology Vol. 46; no. 9; pp. 9607 - 9623
• Main Authors: Minciună, Ioan-Alexandru, Tomoaia, Raluca, Mihăilă, Dragos, Cismaru, Gabriel, Puiu, Mihai, Roșu, Radu, Simu, Gelu, Frîngu, Florina, Irimie, Diana Andrada, Caloian, Bogdan, Zdrenghea, Dumitru, Pop, Dana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.08.2024; MDPI
• Subjects: atrial cardiomyopathy; Atrial fibrillation; atrial remodeling; Dapagliflozin; Dextrose; Diabetes therapy; Glucose; Heart; heart failure; Review; SGLT2 inhibitors; Type 2 diabetes; heart failure; atrial remodeling; atrial fibrillation; atrial cardiomyopathy; SGLT2 inhibitors
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46090571

Atrial cardiomyopathy and remodeling play pivotal roles in the development of atrial fibrillation (AF) and heart failure (HF), involving complex changes in atrial structure and function. These changes facilitate the progression of AF and HF by creating a dynamic interplay between mechanical stress and electrical disturbances in the heart. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for the management of type 2 diabetes, have demonstrated promising cardiovascular benefits, being currently one of the cornerstone treatments in HF management. Despite recent data from randomized clinical trials indicating that SGLT2is may significantly influence atrial remodeling, their overall effectiveness in this context is still under debate. Given the emerging evidence, this review examines the molecular mechanisms through which SGLT2is exert their effects on atrial remodeling, aiming to clarify their potential benefits and limitations. By exploring these mechanisms, this review aims to provide insights into how SGLT2is can be integrated into strategies for preventing the progression of atrial remodeling and HF, as well as the development of AF.